Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells

Quanri Jin1, Linda X Yuan, Delphine Boulbes

  • 1Department of Breast Medical Oncology, The University of Texas M, D, Anderson Cancer Center, Houston, TX 77030, USA. qjin@mdanderson.org

Abstract

Insights

Fatty acid synthase (FASN) phosphorylation by human epidermal growth factor receptor 2 (HER2) drives breast cancer progression. Inhibiting this interaction with lapatinib or C75 may offer a novel therapeutic strategy for HER2-overexpressing breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Human epidermal growth factor receptor 2 (HER2) is a key target in breast cancer therapy.
  • HER2 overexpression enhances fatty acid synthase (FASN) translation, promoting cell growth.
  • The precise molecular mechanisms regulating HER2 and FASN interaction remain unclear.

Purpose of the Study:

  • To investigate the hypothesis that HER2 directly phosphorylates FASN.
  • To elucidate the role of FASN phosphorylation in breast cancer progression.
  • To explore the therapeutic potential of targeting the HER2-FASN interaction.

Main Methods:

  • Mass spectrometry identified FASN as a lapatinib-dephosphorylated protein in SKBR3 cells.
  • Immunofluorescence, immunoprecipitation, Western blotting, and kinase assays were employed.
  • FASN enzymatic activity, invasion, and cell viability assays were conducted using SKBR3 and BT474 cells.

Main Results:

  • FASN was found to be phosphorylated when complexed with HER2.
  • Heregulin induced FASN phosphorylation and increased its enzymatic activity in HER2-overexpressing cells.
  • Lapatinib and the FASN inhibitor C75 blocked FASN phosphorylation and activity, inhibiting matrix metallopeptidase 9 and cell invasion.

Conclusions:

  • FASN phosphorylation by HER2 is a critical factor in breast cancer progression.
  • Targeting FASN phosphorylation by HER2 presents a potential novel therapeutic strategy.
  • This interaction is particularly relevant in HER2-overexpressing breast cancers.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphorylation01:02

Phosphorylation

The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...